UPDATE: Tiziana Life Sciences (TLSA) Reports Plans for Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab
Go back to UPDATE: Tiziana Life Sciences (TLSA) Reports Plans for Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab| (NASDAQ: TLSA) | Delayed: 0.75 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.75 | 52 Week High | $ | |||
| Open | $0.75 | 52 Week Low | $ | |||
| Day High | $0.75 | P/E | N/A | |||
| Day Low | $0.75 | EPS | $ | |||
| Volume | 300,571 | |||||
